Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results. (Q48352479)
Jump to navigation
Jump to search
scientific article published in January 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results. |
scientific article published in January 2007 |
Statements
Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results (English)